{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Complete Response Rate, as determined by LUGANO 2014 criteria, at (reported as number of participants with a CR at 4 months).\n\nThe Lugano classification is utilized for both lymphoma staging and response assessment and incorporates PET-CT imaging. A complete response requires disappearance of metabolically active sites of disease.","groups":[{"description":"Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.\n\nNivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \\[IgG4\\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens.\n\nCabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms).","id":"OG000","title":"Nivolumab + Cabiralizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects with measurable disease who received at least one cycle of treatment and had disease re-evaluated","reportingStatus":"POSTED","timeFrame":"four months","title":"Complete Response Rate at Four Months (LUGANO 2014) Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}